Table 1.

Population, Intervention, Control, Outcome, Study Design (PICOS) inclusion criteria.

Population	Men with localized (T1-T2, N0-Nx, M0) and locally advanced (T3-T4, N0-Nx, M0) prostate cancer
Intervention	CFRT and HFRT, either with 3D-CRT or IMRT
Control	A control group of CFRT, either as a lower total dose (when compared to dose escalated CFRT), or when compared to HFRT
Outcomes
Efficacy	FFBF at 5-year and at 10-year actuarial FU, stratified by risk groups Phoenix definition preferred ASTRO definition may only be used if there is ≥5 year median FU May also have other patient outcomes: OS, DM, CSM @ 5-year and @ 10-year actuarial FU
Safety	Acute RTOG (or similar scale) toxicities, GI and GU Late RTOG (or similar scale) toxicities, GI and GU
Study design
	Large (n > 150), prospective, start of enrollment year ≥ 1990

Abbreviations: 3D-CRT: 3 dimensional conformal radiation therapy; ASTRO: American Society for Radiation Oncology (3 consecutive rises); BED: biologically equivalent dose; CFRT: conventionally fractionated radiation therapy; CSM: cancer specific mortality; FFBF: freedom from biochemical failure; DM: distant metastasis; FU: follow-up; GI: gastrointestinal; GU: genitourinary; HFRT: hypofractionated radiation therapy; IMRT: intensity modulated radiation therapy; OS: overall survival; RTOG: Radiation Therapy Oncology Group